X-linked adrenoleukodystrophy (X-ALD) is a fatal, axonal demyelinating, neurometabolic disease. It results from the functional loss of a member of the peroxisomal ATP-binding cassette transporter subfamily D (ABCD1), which is involved in the metabolism of very long-chain fatty acids (VLCFA). Oxidative damage of proteins caused by excess of the hexacosanoic acid, the most prevalent VLCFA accumulating in X-ALD, is an early event in the neurodegenerative cascade. We demonstrate here that valproic acid (VPA), a widely used anti-epileptic drug with histone deacetylase inhibitor properties, induced the expression of the functionally overlapping ABCD2 peroxisomal transporter. VPA corrected the oxidative damage and decreased the levels of monounsaturated VLCFA (C26:1 n-9), but not saturated VLCFA. Overexpression of ABCD2 alone prevented oxidative lesions to proteins in a mouse model of X-ALD. A 6-month pilot trial of VPA in X-ALD patients resulted in reversion of the oxidative damage of proteins in peripheral blood mononuclear cells. Thus, we propose VPA as a promising novel therapeutic approach that warrants further clinical investigation in X-ALD.
INTRODUCTION
With an incidence of 1 in 17 000 males, X-linked adrenoleukodystrophy (X-ALD, OMIM number 300100) is the most common monogenic leukodystrophy and peroxisomal disorder. It is characterized by axonopathy in the spinal cord, demyelination in the cerebral hemispheres and adrenal insufficiency. X-ALD patients accumulate saturated, and to a lesser extent monounsaturated, very long-chain fatty acids (VLCFA) in plasma and tissues, most notably in the brain and adrenal cortex (1, 2) . The two main neurological phenotypes of X-ALD are the lethal childhood cerebral form (cALD) and the more slowly progressive adrenomyeloneuropathy (AMN) of adults. Although cALD is characterized by severe cerebral demyelination and neuroinflammation, AMN typically shows distal axonopathy in the spinal cord with little or no demyelination (1) . X-ALD is due to mutation in the peroxisomal ATPbinding cassette transporter subfamily D1 (ABCD1) gene (3) . ABCD1 has been proposed to play a crucial role transporting VLCFA, or their CoA derivatives, into peroxisomes in humans. This is based on the accumulation of VLCFA in patients with X-ALD, and the role of the ABCD transporter orthologs in the peroxisomal import of fatty acids in yeast (4, 5) . Recent studies support this hypothesis, as the overexpression of human ABCD1 in Saccharomyces cerevisiae cells allows the import of several acyl-CoA esters of LCFA and VLCFA, such as C18:1v9, C16:0, C22:0 and C24:6v3 into yeast peroxisomes (6) .
Allogenic hematopoietic cell transplantation is to date the only effective therapy when performed at an early stage of demyelination (7, 8) . Very recently, Cartier et al. (9) have shown that lentiviral-mediated gene therapy of hematopoietic stem cells can provide clinical benefits in X-ALD, although sharing the same restrictions in terms of a narrow window of opportunity with the allogenic hematopoietic transplant. Thus, finding a treatment for the vast majority of patients remains a challenge. In human genetic disease, a protein with overlapping functions to those of the defective protein may represent a promising therapeutic option. This is best exemplified in b-globin disorders (10), Duchenne's muscular dystrophy (11) , or the stimulation of survival of motorneuron 2 (SMN2) transcription and the correction of SMN2 splicing by histone deacetylase (HDAC) inhibitors as a potential therapy for spinal muscular atrophy (12, 13) . Functional redundancy is also observed in the peroxisomal ATP-binding cassette transporter subfamily D composed of four predicted peroxisomal transporters (ABCD1 to ABCD4) (14) . The ABCD2 transporter shows the highest similarity (88%) to ABCD1 (15, 16) . The possible functional equivalent of ABCD1 and ABCD2 has been suggested by in vitro (17, 18) , ex vivo in brain tissue (19) and in vivo experiments (20) . Indeed, transgenic ABCD2 overexpression in Abcd1-deficient mice prevents all biochemical, neuropathological and neurological signs of disease that characterize the X-ALD mouse model (Abcd1 2 mice) (20, 21) . These experiments provided proof of principle to attempt pharmacological induction of ABCD2 as a therapeutic strategy. Most successful strategies to induce expression of the ABCD2 gene in vivo involved dietary treatment of Abcd1-deficient mice with the HDAC inhibitor 4-phenylbutyrate (4-PBA). Induction of ABCD2 mRNA correlated with partial correction of VLCFA in the brain and adrenal glands (17) . These effects of 4-PBA on ABCD2 expression were shown to be mediated by HDAC inhibition at the promoter level (22) . A clinical trial was conducted to investigate the effect of 4-PBA in seven patients with AMN (1), although the treatment neither corrected the VLCFA profiles nor induced ABCD2 expression in blood cells. This was attributed to the very short terminal half-life of the drug (1, 23) .
In our study, we decided to investigate the effect of valproic acid (VPA), an unspecific HDAC inhibitor, in patients with X-ALD. VPA is able to cross the blood -brain barrier and has been in clinical use for more than 3 decades to treat epilepsy, mood disorders and migraine (24, 25) . VPA has demonstrated to increase neurite outgrowth and to exert neuroprotective effects on glutamate-induced excitotoxicity in vitro (26, 27) . Significant clinical improvements have been recently reported on a subset of spinal muscular atrophy patients upon VPA treatment (28) (29) (30) .
Oxidative stress might be a major factor in the pathogenesis of adrenoleukodystrophy. In a mouse model of X-ALD, in which we observe an 'AMN-like' phenotype (20, 21) , we have demonstrated oxidative damage to proteins in the spinal cord (31) . This occurs as early as 3.5 months of age, .1 year before neurological symptoms or neuropathological signs appear. We have also shown that an excess of saturated VLCFA triggers free radical production in vitro and ex vivo in an organotypic spinal cord slice culture system (31) .
In the present study, we performed in vivo and in vitro experiments to show that VPA induces ABCD2 gene expression in the fibroblasts of X-ALD patients and reduces oxidative damage to proteins. Antioxidant effects on peripheral mononuclear patient cells indicate that VPA might constitute a promising novel therapeutic approach for X-ALD, particularly for patients suffering from AMN.
RESULTS

VPA induces ABCD2 gene expression in human X-ALD fibroblasts via an HDAC inhibitory mechanism
Human X-ALD fibroblasts were cultured in the presence of VPA (2 mM) for 2 and 12 days, as described previously (12) , and the effect of VPA on the expression of members of the ABCD transporter subfamily was measured. A 2.8-fold increase in ABCD2 mRNA levels in X-ALD fibroblasts was observed after 2 days of treatment with VPA (Fig. 1A) . Similar results were obtained when fibroblasts were treated with VPA for longer periods of time (12 days of culture, data not shown). Much like ABCD2, the ABCD3 peroxisomal transporter has been shown to be able to correct the defect in peroxisomal b-oxidation in ABCD1-deficient cells from X-ALD patients, when it is overexpressed by transient transfection (32) . Less information is available on ABCD4, except for the finding that ABCD4 expression levels in the brain of X-ALD patients are inversely correlated with phenotype severity (33) . In X-ALD fibroblasts cultures, we were able to measure a 1.4-fold increase in ABCD3 mRNA levels after treatment with VPA. In contrast, ABCD4 mRNA expression was not affected by VPA (Fig. 1A) . As to investigate whether induction of ABCD2 expression by VPA was mediated through HDAC inhibitory mechanisms, we used a control drug (34) . The molecular structure of valpromide (VPD or 2-propylpentanamide), the amide derivative of VPA (2-propylpentanoic acid), is almost identical to that of VPA. However, VPD does not exhibit HDAC inhibitory properties (35, 36) . ABCD2 gene expression was not induced by VPD (Fig. 1B) , suggesting that the effect of VPA on ABCD2 gene transcription was most likely mediated through inhibition of HDAC.
ABCD2 overexpression in Abcd1
2
/Abcd2
2/2 mice prevents protein oxidative damage in the spinal cord There is mounting evidence that oxidative burden plays a major role in the initial steps of the X-ALD pathogenesis cascade (31, (37) (38) (39) . We recently demonstrated oxidative damage of proteins in vivo in the spinal cord of X-ALD mice at 3.5 months of age, well before the onset of neuropathological signs or neurological symptoms, which can be detected at 16 and 20 months, respectively (31) . Specific and well-characterized markers of direct oxidation of carbonyl residues such as glutamic semialdehyde (GSA) (derived from the metal-catalyzed oxidation of proline and arginine) and aminoadipic semialdehyde (AASA) (which results from lysine oxidation) (40) were used. Both carbohydrates and polyunsaturated fatty acids, when reacting with free radicals, generate highly reactive dicarbonyl compounds. These in turn produce specific, non-enzymatic adducts when reacting with proteins, such as N (41) . The lipid peroxidation product MDAL has been shown to accumulate in the Abcd1 null mouse spinal cord as early as 3.5 months of age. At 12 months of age, additional markers of protein oxidative lesions, such as AASA, GSA (direct carbonylation), CEL and CML (glycoxidation/lipoxidation), are also increased (31) . To determine whether ABCD2 overexpression is able to ameliorate oxidative lesions in vivo, we used a transgenic mouse line overexpressing ABCD2 under the control of the ubiquitous chicken b-actin promoter (20) . These mice were crossed with the doubleknockout Abcd1
2
/Abcd2
2/2 mice to generate triple mutant mice (Abcd1
2
/Abcd2
2/2 /TgAbcd2+). We had formerly reported that expression levels of the ABCD2 protein in spinal cord increased 5 -10-fold over the baseline level and prevented accumulation of saturated VLCFA in organs and the onset of axonal degeneration (20) . Here, we quantified oxidative lesion markers in double and triple mutants, and detected even higher amounts of MDAL in the Abcd1 
2/2 / TgAbcd2+ mice (Fig. 1C) .
VPA corrects levels of oxidative lesion markers in X-ALD fibroblasts
In X-ALD patients, the same types of protein oxidative lesions as described in spinal cord occur in fibroblasts and are exacerbated by C26:0 exposure (31) . To investigate whether the observed VPA induction of ABCD2 expression correlated with amelioration of the oxidative damage to proteins, we quantified the markers of each pathway of protein oxidative damage (31) . After 7 days of treatment of X-ALD fibroblasts with VPA, the carbonylation and glycoxidation/lipoxidation 
/Abcd2
2/2 and Abcd1 2 /Abcd2 2/2 /TgAbcd2 spinal cord at 11 months of age (n ¼ 4 per genotype). VPA corrects levels of oxidative lesion markers in patients' fibroblasts (D). GC/MS analysis of protein carbonylation (AASA and GSA), glycoxidation (CML and CEL) and lipoxidation (MDAL) markers, quantified in human control and X-ALD fibroblasts (n ¼ 4 per genotype and condition), after 7 days of treatment with VPA (2 mM). Significant differences have been determined by ANOVA followed by Tukey's HSD post hoc ( * P ≤ 0.05, * * P ≤ 0.01 and * * * P ≤ 0.001).
markers of oxidative damage were significantly decreased or normalized (Fig. 1D ).
Effects of VPA on fatty acid metabolism
As VPA is able to stimulate expression of ABCD2 mRNA, the expected consequence would be normalization of the saturated VLCFA levels, as it has been shown in vitro (17, 18, 42) and in vivo after ABCD2 overexpression (20) . Increased levels of saturated hexacosanoic acid (C26:0), and tetracosanoic acid (C24:0), together with an increased C26:0/ C22:0 ratio, are traditionally considered the most reliable diagnostic biochemical markers for X-ALD. VPA did not change the cellular levels of saturated VLCFA, such as C26:0 ( Fig. 2A) or C24:0 (data not shown) in fibroblasts. In contrast, VPA reduced the abnormal accumulation of C26:1v9, a monounsaturated VLCFA by 40% (Fig. 2A) . C26:1v9 also accumulates in the plasma and brain of X-ALD patients, although to a lesser extent ( 2-fold over the baseline) than saturated C26:0, whose levels can be 5 -7-fold higher in patients than in control individuals (2, 43) . This raises the possibility that the antioxidant effects observed after VPA treatment might be at least partially mediated by a decrease in unsaturated VLCFA.
Ex vivo effects of VPA on ABCD2 gene expression and VLCFA levels
As the half-life of VPA in rodents is very short (2.5 h in rodents compared with 8 -10 h in humans) (44), we used an ex vivo rather than an in vivo system to assess the effects of VPA on ABCD2 gene. Rat organotypic hippocampal slice cultures (OHSCs) are often used as a drug screening and drug validation tool (45, 46) . Treating rat and mouse OHSCs with 2 mM of VPA for 2 days resulted in a 2.1-fold increase in Abcd2 gene expression (Fig. 2B) . A similar effect (induction just below 2-fold) was found in OHSCs from Abcd1 null mice. To investigate whether VPA could also induce ABCD2 expression in the adult human hippocampal brain, slices obtained after epilepsy surgery were cultured on the same media used for the rat OHSC experiments and were treated with 2 mM VPA for 48 h. Treatment induced on average a 4-fold increase in ABCD2 gene expression (Fig. 2B) . Doses of VPA of 0.8 mM were sufficient to double the expression levels of ABCD2 (Supplementary Material, Fig. S1 ). Interspecies differences might account for the higher increase in ABCD2 in human slices. Next, we investigated whether C26:1v9 and C26:0 were modulated by VPA. OHSCs from 4-week-old wild-type, Abcd1-knockout and double-knockout Abcd1/Abcd2 mice were generated. As both C26:0 and C26:1v9 are increased in Abcd1 
/Abcd2
2/2 -derived cells, the brain specimens from double-knockout mice might offer information on the effects of VPA, independent of ABCD2 expression. After 12 days incubation with VPA, expression of the Abcd2 gene increased about 2-fold in Wt and Abcd1 2 OHSCs (Fig. 2B ), but was not measurable in OHSCs from Abcd1 2 /Abcd2 2/2 mice, most likely due to mRNA decay (data not shown) (20) . The concentration of C26:1v9, but not of C26:0, decreased by 25% in Abcd1 2 OHSCs (Fig. 2C ). This decrease in C26:1v9 concen- mice, suggesting that the decrease in C26:1v9 after VPA treatment is dependent on ABCD2 function (Fig. 2C) .
Unsaturated VLCFA generates more reactive oxygen species than saturated VLCFA in human X-ALD fibroblasts
We previously reported that excess C26:0 generates reactive oxygen species (ROS) and redox imbalance in control and X-ALD human fibroblasts (31) . We investigated whether C26:1v9 would also be able to generate free radicals in vitro. Using dichlorofluorescein diacetate as a probe, we quantified the levels of superoxide anions (O 2
2
) in human X-ALD fibroblasts incubated with C18:1v9, C24:1v9, C26:1v9 and C26:0. The levels of ROS were 3-fold higher in fibroblasts incubated with C26:1v9 than in the fibroblasts incubated with other fatty acids at similar concentrations. C24:1v9 did not generate ROS, indicating that the size of the aliphatic chain is important for ROS production (Fig. 2D) . Thus, the doubling of C26:1v9 levels observed in X-ALD fibroblasts and brain is likely to significantly contribute to ROS generation in vivo, even though C26:1v9 accumulation in fibroblasts was less pronounced than the accumulation of C26:0 in the plasma and organs analyzed.
VPA treatment induces elongase gene expression
As an HDAC inhibitor, VPA is thought to act at the transcriptional level on some 10% of coding genes (47) . As the fatty acid content of the cell is a product of fatty acid synthesis and degradation, we hypothesized that VPA could induce the expression of genes involved in the synthesis of saturated VLCFA and eventually 'mask' the expected benefit from the increased catabolism of C26:0 mediated via ABCD2 up-regulation.
In mammalian tissues, VLCFA are synthesized from LCFA by elongases. Seven human elongases have been identified (ELOVL1 -7), strongly conserved genes between mouse and human genomes (48, 49) . The effect of VPA on the level of expression of different elongase genes was evaluated by realtime quantitative PCR in human X-ALD fibroblasts. The expression of ELOVL3, ELOVL4 and ELOVL5 genes was increased between 1.5-and 2.5-fold after VPA treatment, both in X-ALD and control fibroblasts (Fig. 3) . ELOVL4 has been reported to catalyze the elongation of C26:0 to C28:0 and C28:0 to C30:0 (50,51), whereas ELOVL3 mediates the elongation of C22:0 to C24:0 and C24:0 to C26:0 in vivo (48) . Interestingly, ELOVL3 transcriptional regulation has been shown to depend on the expression of ABCD2 in the mouse liver (52) . In contrast, the expression of ELOVL1 gene was not sensitive to VPA administration. ELOVL2, ELOVL6 and ELOVL7 expression was not detected in human fibroblasts.
We next tested the influence of VPA on the enzyme stearoyl-coenzyme A desaturase (SCD), which is also involved in the synthesis of monounsaturated fatty acids from saturated fatty acids. In human fibroblasts, VPA did not modify the expression of the SCD gene (Fig. 3) . These results suggest that VPA could stimulate the elongation of saturated fatty acids via increased transcription of ELOVL3, ELOVL4 or ELOVL5 but not of ELOVL1 or SCD genes. This provides a plausible mechanism for the lack of effect of VPA on C26:0 levels.
VPA decreases markers of oxidative damage in peripheral blood mononuclear cells in X-ALD patients
Five X-ALD patients were treated with VPA for 6 months, after providing appropriate informed consent and approval by the Ethics Committee of Hôpital Saint Vincent de Paul, Paris. X-ALD patients were given oral VPA (Depakine) at 40 mg/kg/day.
The ABCD2 mRNA levels in peripheral blood mononuclear cells from treated X-ALD patients were measured before (t ¼ 0), and 6 months after (t ¼ 6), VPA treatment commenced. We found that ABCD2 mRNA levels increased 1.2 -2.1-fold above baseline levels (Fig. 4A) .
We also measured the markers of oxidative damage in the mononuclear cells from untreated normal individuals and from X-ALD patients, before and after VPA treatment ( Fig. 4B and C) . At baseline, compared with normal individuals, the levels of GSA, AASA and MDAL were 1.3-2.4-fold higher in X-ALD patients (Fig. 4B) . Treatment with VPA for 6 months corrected the levels of AASA, CML and CEL, and markedly decreased the levels of GSA and MDAL (Fig. 4C) . The concentrations of C26:0 and C26:1v9 in the mononuclear cells from X-ALD patients treated with VPA did not change (Supplementary Material, Fig. S2 ).
DISCUSSION
Oxidative damage is a common feature of neurodegenerative disease, with a proven role in the pathology of diseases, such as amyotrophic lateral sclerosis and Parkinson's disease (53, 54) . In the X-ALD mouse model that mimics AMN, time course experiments have provided compelling evidence of oxidative damage of proteins very early in life, at 3 months of age, long before the neuropathological and neurological signs of disease occur (31) . As the neurodegenerative process evolves, axonal degeneration with accumulations of Figure 3 . Elongases (ELOVL1, 3, 4 and 5) and Delta9-desaturase or SCD expression levels in human control (n ¼ 4) and X-ALD (n ¼ 5) fibroblasts treated with VPA (2 mM) for 2 days. Expression levels were compared with control cells by quantitative RT-PCR and normalized to 36B4. Data are represented as mean + SD. Significant differences have been determined by ANOVA followed by Tukey's HSD post hoc ( * P ≤ 0.05, * * P ≤ 0.01 and * * * P ≤ 0.001).
amyloid precursor protein and synaptophysin in axonal swellings appear. Additional evidence of the contribution of oxidative damage to the neurodegenerative cascade of X-ALD has been reported in post-mortem brain samples from patients with cerebral ALD, which show increased immunoreactivity to markers of lipoxidative damage (37) , and in the plasma of X-ALD patients using the thiobarbituric acid test (39) . Thus, oxidative damage could be linked to both the initiation and the progression of X-ALD neurodegeneration. The origin of this oxidative damage is being intensively studied. Current evidence points to the excessive production of free radicals due to the accumulation of hexacosanoic acid and to an impaired response of the antioxidant defense system(s) to oxidative insults. The latter defect is illustrated by the following experiments: (i) X-ALD fibroblasts die more quickly following glutathione depletion than their control cell lines; and (ii) excess C26:0 produces ROS in X-ALD and control fibroblasts, but oxidative lesions of proteins are generated in X-ALD cells only (31) . Although initial experiments have demonstrated the role of saturated hexacosanoic acid C26:0 in triggering oxidative stress and damage in fibroblasts, data from the current study reveal that the monounsaturated C26:1 fatty acid, which also accumulates in X-ALD, is a more powerful inducer of ROS in vitro than C26:0. Moreover, we show that VPA ameliorates oxidative lesions to proteins without affecting levels of hexacosanoic acid, but decreasing the levels of C26:1v9 instead.
These results indicate that the excess saturated VLCFA might not be the sole cause of oxidative damage in X-ALD and underline the role played by C26:1v9 and possibly, by other fatty acids transported across the peroxisomal membranes by the ABCD1 transporter. This is in line with recent observations indicating that ABCD1 is capable of importing a range of LCFA and VLCFA when overexpressed in yeast (6) . These findings are of particular relevance to Lorenzo's oil, the dietary therapy in current use for X-ALD. The oil is a 4:1 mixture of oleic acid (C18:1) and erucic acid (C22:1), both on a glycerol backbone. Treatment with Lorenzo's oil normalizes saturated VLCFA within 4-6 weeks, without halting neurological progression (7) or ameliorating oxidative damage as measured by thiobarbituric acid reactive substances in plasma (55) . Administration of Lorenzo's oil results in a marked increase in C26:1v9 to C32:1v9 fatty acids in the plasma of treated patients (56) . This effect is attributed to an increase in long-chain monounsaturated substrates and subsequent increase in v9-VLCFA elongation from erucic and oleic fatty acids. In view of the presented data, Lorenzo's oil failure to reduce oxidative damage in spite of the decrease in C26:0 could be due to the counteracting effects of lowering C26:0 in one hand, while simultaneously increasing C26:1 levels on the other.
The concept of overlapping functions between ABCD1 and ABCD2 transporters gains strength in this work. We had previously shown that overexpression of ABCD2 prevented accumulation of saturated VLCFA in target organs and disease onset in the mouse, and we currently present compelling evidences indicating that overexpression of ABCD2 prevents oxidative damage to proteins. In this context, amelioration of C26:1v9 levels instead of C26:0 was somewhat unexpected, as we had shown formerly that a transgenic mouse exhibiting constitutive ABCD2 overexpression could normalize the C26:0 levels in tissues (20) . This discrepancy could owe to different mechanisms or the combination of them: (i) VPA raising the synthesis of saturated VLCFA, via increase in transcription of saturated VLCFA elongases (ELOVL3 and ELOVL4); and (ii) levels of induction of ABCD2 achieved by VPA are insufficient to perform with efficacy the import of C26:0 and degradation in peroxisomes. In fibroblasts, the levels of ABCD2 induction were 3-fold in contrast to in vivo observations, in which ABCD2 protein expression increased 5 -10-fold (20) . This suggests a higher AASA, GSA, CML, CEL and MDAL were quantified by GC/MS before (t ¼ 0) and at the end of the trial with VPA (t ¼ 6). Significant differences have been determined by ANOVA followed by Tukey's HSD post hoc ( * P ≤ 0.05, * * P ≤ 0.01 and * * * P ≤ 0.001).
affinity of the transporter for the C26:1 VLCFA, a matter that deserves further investigation. Nevertheless, this increase in ABCD2 expression was sufficient to decrease C26:1 level, correlating with an important decrease in levels of the markers of protein oxidative lesions. In a similar manner, VPA treatment in the clinical setting corrects oxidative damage in peripheral mononuclear cells, independently of VLCFA levels (both saturated and monounsaturated fatty acids), in spite of a mild ABCD2 induction. This opens several possibilities: (i) the shown levels of ABCD2 induction are sufficient to correct oxidative stress by, for instance, transporting an unidentified substrate of ABCD1; (ii) peripheral mononuclear cells are simply not the best cells to analyze the effect of VPA on the VLCFA levels, despite an effect of oxidative lesions; or (iii) VPA might exert antioxidant effects independently of ABCD2. Indeed, VPA has repeatedly been associated with neuroprotective and antioxidant effects in vitro and in vivo, including descriptions of beneficial effects through enhancing mitochondria respiration rate and function in long-term in vivo treatments (57) (58) (59) . On the other hand, it has been sporadically reported to be associated with hepatotoxicity due to oxidative burden (60) . These are adverse effects that can easily be controlled and reverted by using L-carnitine (61) . VPA has therefore always been considered a very safe drug. Our results support the engagement of AMN patients in longer, larger trials to allow clinical evaluation of potential therapeutic benefits.
MATERIALS AND METHODS
Chemicals
Chemicals and glassware analytical-grade chloroform, methanol, n-hexane, acetonitrile, ammonium, hydrochloric acid (fuming, 37%) and acetic acid (glacial, 100%) were obtained from Merck (Darmstadt, Germany). Deionized water was passed through a MilliQ Labo system (Millipore, Bedford, MA, USA). Tetracosanoic acid (C24:1v9), hexacosanoic acid (C26:0) and VPA were purchased from Sigma (St Louis, MO, USA). Deuterium-labeled free fatty acid internal standards 3,3,5,5- (62) . All glassware was acid washed and prior to use rinsed with chloroform containing 1% acetic acid. 6-Carboxy-2 ′ , 7
′ -dichlorodihydrofluorescein diacetate, diacetoxymethyl-ester (H 2 -DCFDA) and VPD were, respectively, purchased from Molecular Probes and Lancaster synthesis.
Mouse breeding
The genotyping of Abcd1 2 and Abcd2 2/2 and transgenic overexpressing ABCD2 mice has been described previously (20, 21) . To obtain double heterozygous mutants, we crossed Abcd1 null females (mutation is on the X chromosome), with Abcd2 2/2 males. Double heterozygous in the F1 generation were intercrossed to obtain double-knockout mice and wild-type littermate controls; the offspring obeyed Mendelian ratios. Mice used for OHSC and fatty acid analysis, and quantification of oxidative lesion markers were on a pure C57BL/6J background (backcrossed at least 12 generations into C57BL/6J). Only male littermates were used for all the experiments. All animals were housed under the same controlled conditions, between 22 and 258C, on a 12 h light/ dark cycle, with free access to food and water. Animals were sacrificed and tissues including brain, spinal cord, sciatic nerve, adrenal gland and liver were snap-frozen in liquid nitrogen and conserved at 2808C. All methods employed in this work are in accordance with the Guidelines for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publications No. 85-23, revised 1996) and with the Ethics Committee of IDIBELL and the Generalitat de Catalunya.
Cell culture
Control and X-ALD human fibroblasts were grown in DMEM containing 10% of fetal bovine serum, 100 U/ml penicillin and 100 mg streptomycin, at 378C in humidified 95% air/5% CO 2 . Unless otherwise stated, experiments were carried out with cells at 95% of confluence. Skin biopsies to prepare the fibroblastic lines were collected according to the institutional guidelines for sampling including informed consent of the persons involved or their representatives.
Organotypic hippocampal slice culture
The hippocampus from 4-week-old mice was immediately removed and placed in ice-cold dissecting media (pH 7.15). Next, the hippocampus was cut into 200 mm thick slices using a McIlwain tissue chopper to generate the organotypic slice cultures and placed into a sterile Petri dish with Grey's balanced salt solution. Hippocampal brain slices were transferred onto Millicell-CM-cultured plate inserts (Millipore). The inserts were placed into wells of a six-well plate containing 1.0 ml of medium containing 50% MEM with Earl's salts and glutamine, 25% Hanks' balanced salt solution and 25% horse serum supplemented with 20 mM of HEPES acid -salt and D-glucose (6 mg/ml) (Gibco-BRL) (63) .
OHSCs derived from 5-day-old Wistar rats were prepared according to interface technique (46) . After dissection of the frontal pole of the hemispheres and the cerebellum, the brains were cut into 350 mm thick horizontal slices on a vibratome (Leica Microsystems, Wetzlar, Germany). For each experiment, three slices were transferred into culture plate insert membranes (BD Biosciences, San Jose, CA, USA) and thereafter into six-well culture dishes (BD Biosciences) containing 1.2 ml culture medium as described in detail by Eyü-poglu et al. (63) . One day after preparation, the culture medium was changed and OHSCs were exposed to the test compound for 48 h and snap-frozen in liquid nitrogen, as described previously (63) . Hippocampal specimens were derived from two patients submitted to epilepsy surgery at the Erlangen Epilepsy Center. The patients suffered from drug-resistant epilepsy and were scheduled for hippocampal resection. VPA treatment was stopped several weeks prior to surgery. For scientific use of tissue specimens, informed consent was obtained from each patient with the approval of the local Ethics Committee of the University Hospital of Erlangen. Surgical specimens were prepared and processed as described for rat OHSCs.
Evaluation of intracellular ROS
Intracellular ROS levels were estimated using the ROSsensitive H 2 -DCFDA probe as described (31) . Following incubation with 10 mM H 2 -DCFDA for 30 min, cells were washed twice with PBS and scraped into water. The fluorescence of H 2 -DCFDA-stained cells was measured with a spectrofluorimeter (excitation wavelength 493 nm, emission wavelength 527 nm). Fatty acids were dissolved in ethanol and added to the medium for 24 h.
Measurement of oxidative lesion markers: GSA, AASA, CML, CEL and MDAL GSA, AASA, CML, CEL and MDAL concentrations in total proteins from spinal cord homogenates or human fibroblasts were measured by gas chromatography/mass spectrometry (GC/MS), essentially as previously reported (31) . The amounts of products were expressed as the ratio of micromole of GSA, AASA, CML, CEL or MDAL/mol of lysine.
Fatty acid determination
Total cellular fatty acids were analyzed by electrospray ionization mass spectroscopy method described by Valianpour et al. (2) .
Synthesis of C26:1v9
C26:1v9 was synthesized from commercially available C24:1v9 using established methods.
RNA extraction and quantitative real-time PCR
Total RNA was extracted using RNeasy Kit (Qiagen) and quantitative PCR experiments were performed according to the manufacturer's instructions (LightCycler, Roche Diagnostics). PCRs were carried out with 36B4 (also called RPL0) used as a standard control gene. Primers used are in Supplementary Material, Table S1 . Data are given as mean + SEM.
Pilot trial with VPA
Five patients with X-ALD were enrolled after assessing normal liver transaminase activities. Four of the patients were affected with demyelinating cerebral adrenoleukodystrophy at ages between 7 and 18 years old. The fifth patient was affected with pure AMN and Addison's disease. Laboratory testing, including a basic chemistry profile, complete blood count with platelets, transaminases, carnitine profile, amylase, lipase and trough VPA levels, was performed at baseline and every 4 weeks following initiation. Dosing of VPA (Depakine), calculated at 40 mg/kg/day, was typical of that used in epilepsy patients (15 -50 mg/kg/day). Patients reported no side effects related to VPA administration and compliance with the treatment was checked by monitoring the serum concentrations of VPA. All treated patients achieved serum concentrations within the range considered therapeutic for epilepsy (70-100 mg/l). Capsules were administered once daily during a 6-month period. Blood samples were taken on the day of starting the treatment (t ¼ 0), 3 months (t ¼ 3) and 6 months later (t ¼ 6). Informed and written consent was obtained from all patients or their legal representatives and studies were approved by the local Ethics Committee of Hôpital Saint Vincent de Paul, Paris.
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